A new under‑the‑skin version of isatuximab is now approved, giving multiple myeloma patients a much faster and more ...

People living with early Alzheimer’s disease can now begin treatment with Leqembi without setting foot in an infusion center.

Y our oncologist may prescribe immunotherapy at various points in the cancer treatment journey. Immunotherapy is known to be especially effective in treating late-stage cancer that hasn’t responded to ...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

Eisai’s full-throttle development of a subcutaneous sibling to recently approved Alzheimer’s disease drug Leqembi could bear fruit in the coming quarters, with the Biogen-partnered drugmaker aiming to ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Once-weekly subcutaneous initiation dosing offers an at-home alternative for adults with MCI or mild dementia due to Alzheimer’s disease, potentially reducing infusion-center dependence and visit ...